These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
393 related articles for article (PubMed ID: 35606821)
41. Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes. Korell F; Berger TR; Maus MV Med; 2022 Aug; 3(8):538-564. PubMed ID: 35963235 [TBL] [Abstract][Full Text] [Related]
42. Adoptive therapy with CAR redirected T cells for hematological malignancies. Li S; Yang Z; Shen J; Shan J; Qian C Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302 [TBL] [Abstract][Full Text] [Related]
43. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641 [No Abstract] [Full Text] [Related]
44. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor. Zuo YH; Zhao XP; Fan XX Pharmacol Res; 2022 Oct; 184():106454. PubMed ID: 36115525 [TBL] [Abstract][Full Text] [Related]
45. CAR-T cells: the Chinese experience. Wang L; Tan Su Yin E; Zhao H; Ni F; Hu Y; Huang H Expert Opin Biol Ther; 2020 Nov; 20(11):1293-1308. PubMed ID: 32605454 [TBL] [Abstract][Full Text] [Related]
46. Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction. Jiang P; Zhang Z; Hu Y; Liang Z; Han Y; Li X; Zeng X; Zhang H; Zhu M; Dong J; Huang H; Qian P Leukemia; 2022 Nov; 36(11):2656-2668. PubMed ID: 35962059 [TBL] [Abstract][Full Text] [Related]
47. Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic. Smirnov S; Mateikovich P; Samochernykh K; Shlyakhto E Front Immunol; 2024; 15():1335424. PubMed ID: 38455066 [TBL] [Abstract][Full Text] [Related]
48. Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells. Badieyan ZS; Hoseini SS Arch Immunol Ther Exp (Warsz); 2018 Aug; 66(4):283-288. PubMed ID: 29427174 [TBL] [Abstract][Full Text] [Related]
49. New CARs on and off the road: challenges and new developments in CAR-T cell therapy. Wehrli M; Maus MV Curr Opin Pharmacol; 2021 Aug; 59():116-126. PubMed ID: 34198161 [TBL] [Abstract][Full Text] [Related]
50. A metabolic switch to memory CAR T cells: Implications for cancer treatment. Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868 [TBL] [Abstract][Full Text] [Related]
51. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma. Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256 [TBL] [Abstract][Full Text] [Related]
52. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292 [TBL] [Abstract][Full Text] [Related]
53. Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies. Xiao X; Wang Y; Zou Z; Yang Y; Wang X; Xin X; Tu S; Li Y Front Immunol; 2022; 13():954235. PubMed ID: 36091028 [TBL] [Abstract][Full Text] [Related]
54. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
55. Activation-induced cell death in CAR-T cell therapy. Huan T; Chen D; Liu G; Zhang H; Wang X; Wu Z; Wu Y; Xu Q; Yu F Hum Cell; 2022 Mar; 35(2):441-447. PubMed ID: 35032297 [TBL] [Abstract][Full Text] [Related]
57. The journey of CAR-T therapy in hematological malignancies. Lu J; Jiang G Mol Cancer; 2022 Oct; 21(1):194. PubMed ID: 36209106 [TBL] [Abstract][Full Text] [Related]
58. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. Schultz L Front Immunol; 2020; 11():1985. PubMed ID: 32849662 [TBL] [Abstract][Full Text] [Related]